The World Health Organization predicts that cardiovascular diseases will be the leading causes of mortality and morbidity in developing countries by the year 2020.[@b1-asm-1-9]--[@b4-asm-1-9] The Gulf Heart Association (GHA) has recognized the seriousness of this issue and the devastating impact of such illnesses. Its landmark multinational study launched in May 2006, the Gulf Registry of Acute Coronary Events (Gulf RACE), demonstrated several unique features and knowledge-care gaps in the acute coronary syndrome (ACS) population in Gulf nations.[@b5-asm-1-9] It also identified a high prevalence of cardiovascular risk factors and low rates of revascularization procedures, but low in-hospital mortality.[@b6-asm-1-9]

The objectives of this second phase (Gulf RACE-2) were to take another snapshot of ACS care in the Arabian Gulf region, but with a more detailed data collection on the left ventricular function and the coronary anatomy, in addition to determining the 30-day and 1-year total mortality rates. All Arabian Gulf countries were involved in both phases of the registry, except for Saudi Arabia in the previous phase and Kuwait in the currently reported phase 2.

PATIENTS AND METHODS
====================

The data were collected from a 9-month prospective, multicenter study of Gulf RACE-2 that recruited consecutive ACS patients from 6 adjacent Middle Eastern Gulf countries (Bahrain, Saudi Arabia, Qatar, Oman, United Arab Emirates \[UAE\], and Yemen). Patients were recruited from 65 hospitals with a diagnosis of ACS including unstable angina (UA) and non--ST-elevation myocardial infarction (data merged as NSTEACS), and ST-elevation myocardial infarction (STEMI). An on-site cardiac catheterization laboratory was available in 43% of hospitals. The majority of hospitals (71%) had a coronary care unit on-site. No patient-specific exclusion criteria were available, and all prospective patients with ACS were thus enrolled. The study received ethical approval from the institutional ethical bodies in all participating countries. Full details of the methods have been published.[@b5-asm-1-9],[@b6-asm-1-9]

The diagnosis of the different types of ACS and definitions of data variables were based on the American College of Cardiology clinical data standards.[@b7-asm-1-9] Central obesity was defined as a waist circumference of more than 94 cm in men and more than 80 cm in women.[@b8-asm-1-9] Data on additional variables were collected in the second phase of the registry compared to the previous phase, and included the following: serum creatinine before hospital discharge, serum hemoglobin A1c, fondaparinux, bivalirudin, echocardiography results (severe left ventricular \[LV\] dysfunction: ejection fraction \[EF\] \<30%; moderate LV dysfunction: EF=30%--40%; mild LV dysfunction: EF=40%--55%; normal LV function: EF \>55%\], coronary angiogram results \[left main coronary artery disease \[CAD\], 1-vessel disease, 2-vessel disease, 3-vessel disease), and types of coronary artery stents used (drug-eluting and/or bare-metal stents). Significant CAD was defined as ≥50% occlusion compared to the normal reference diameter in the left main, and ≥70% in other major epicardial coronary arteries.

A case report form for each patient with suspected ACS was filled out upon hospital admission by assigned physicians and/or research assistants working in each hospital, using standard definitions and completed throughout the patient's hospital stay. Almost all the data variables were mandatory fields and completed online. All case report forms were verified by a cardiologist, and then sent online to the principal coordinating center, where they were further checked for errors before submission for final analysis. We avoided duplicate admissions to the registry by using patients' national identification numbers and assigned "registry numbers." A long-term mortality was obtained by either phone contacts or clinic visits. For "therapy-related timelines" in STEMI patients who underwent thrombolytic therapy (TT) or primary percutaneous coronary intervention (PCI), we excluded transferred STEMI patients because of inaccurate data from other hospitals not involved in the registry.

Data were summarized as mean (SD) if they were normally distributed; otherwise, they were summarized as the median and interquartile range (IQR). Differences between groups were assessed using the chi-square or Fisher exact tests for categorical variables, student t tests for continuous and normally distributed variables, and the Mann-Whitney U test for skewed variables. All analyses were considered significant at *P*\<.05. The analysis was performed using SPSS software, version 17 (IBM Corp., Armonk, NY USA).

RESULTS
=======

Study Population Characteristics
--------------------------------

Between October 2008 and June 2009, 7930 ACS patients were enrolled. There were 3613 (45.6%) STEMI and 4317 (54.4%) NSTEACS patients. The NSTEACS patients included 2386 (55.3%) NSTEMI and 1931 (44.7%) UA patients. [Table 1](#t1-asm-1-9){ref-type="table"} shows patient baseline characteristics, treatments, and outcomes. The mean age (standard deviation \[SD\]) of the overall population was 56 (17) years, 71.2% were Arabian Gulf citizens, and 78.8% were men. The prevalence of CAD risk factors was high; 39.5% had diabetes mellitus (DM), 47.2% had hypertension, 52.9% were either current or ex-smokers, 18.4% were khat chewers, and 32.7% had hyperlipidemia. The mean body mass index (BMI \[SD\]) was 26.2 (5.3) kg/m^2^, and 50.1% of patients had central obesity. Upon presentation, only 19.1% arrived at the hospital in an ambulance, 84.1% had typical ischemic chest pain, 23% had clinical evidence of congestive heart failure (CHF), and 68.4% had positive serum troponin. Serum troponin was unknown in 796 (10%) patients as the treating physicians decided not to perform the test because the diagnosis of STEMI had already been made by electrocardiogram, myocardial infarction was diagnosed by elevated creatinine kinase (CK)-MB, or the test was not available at the time of admission.

Compared with STEMI patients, those with NSTEACS were more likely to be older and an Arabian Gulf citizen; have a higher BMI, central obesity, history of CAD, PCI, coronary artery bypass graft surgery (CABG), peripheral arterial disease, CHF, DM, hypertension, ex-smoking, hyperlipidemia, and/or cerebrovascular accident or transient ischemic attack; present with atrial fibrillation, Killip class \>1, higher mean systolic blood pressure; higher frequency of intermediate Global Registry of Acute Coronary Events (GRACE) score category, have severe LV dysfunction, had undergone coronary angiogram, PCI, CABG, and/or left main and/or 3-vessel disease during hospitalization (*P*\<.001 for all comparisons). However, STEMI patients were more likely to be men, current smokers, and khat chewers and to present with typical ischemic chest pain or cardiac arrest, positive serum troponin, higher peak serum CK-MB fraction, low-density lipoprotein, creatinine, and low GRACE score category (*P*\<.001 for all comparisons).

ST-elevation myocardial infarction: presentation and management
---------------------------------------------------------------

A total of 2416 (79.3%) out of 3047 STEMI patients presented within 12 hours of symptom onset. The median time from symptom onset to hospital arrival was 178 minutes (IQR 210). A total of 1585 patients (65.7%) were treated with TT, with 34% receiving it within 30 minutes of hospital arrival, and the median door-to-needle time was 39 minutes (IQR 36). The most commonly used TT was reteplase (44.2%), followed by streptokinase (42.5%), then tenecteplase (10.2%). These drugs were administered in coronary/intensive care units in 58.2%, and by cardiology specialists in 84.4% of cases. There was no clinical evidence of reperfusion in 10.2%, and rescue PCI was done in 13.3% of these patients. Reasons for not administering TT included: symptom onset more than 12 hours before hospital presentation (48.5%), primary PCI (22.3%), absolute contraindications (10.5%), and missed diagnosis (6%). Other causes (12.8%) that the treating physicians reported included one or more of the following: "very elderly" patients, severe hypertension, prolonged resuscitation, cardiogenic shock, cardiac arrest, transient ST-segment elevation, unavailability of TT, patient and/or family refusal, and patient inability to pay for cardiac care. Regarding primary PCI, median door--to-balloon time (DBT) was 87 minutes (IQR 63), and 52.4% of the patients had a DBT of less than 90 minutes following hospital arrival.

Medications
-----------

[Figures 1](#f1-asm-1-9){ref-type="fig"} and [2](#f2-asm-1-9){ref-type="fig"} show the high use of evidence-based medications in the first 24 hours of hospital admission and at discharge: aspirin (98.3% and 95.4%), statins (94.7% and 91.2%), clopidogrel (76% and 68%), beta-blockers (73% and 79.2%), and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (74.8% and 78.1%). [Figure 3](#f3-asm-1-9){ref-type="fig"} shows that most patients received anticoagulation therapy; for more than half, therapy was intravenous unfractionated heparin, and for less than 1%, it was either fondaparinux or bivalirudin. Intravenous glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa--I) were given in 14.3%, mostly in the form of tirofiban.

Procedures and outcomes
-----------------------

Echocardiography was done in 76.5% of patients, with 73.7% having evidence of LV dysfunction, coronary angiography in 32.5%, PCI in 21% (scheduled PCI in 1.43%), and CABG in 2.9% (scheduled CABG in 4.7%). In PCI patients, bare-metal stents were used in 40.6%, drug-eluting stents in 56.6%, and both in 2.8%. The overall in-hospital mortality was 4.6%. The most frequent complications were recurrent ischemia (15.5%) and CHF (13.1%), whereas rates of stroke (0.7%) and major bleeding (0.6%) were very low. STEMI patients had higher in-hospital mortality and cardiovascular complications (*P*=.006 for CHF, and P\<.001 for all other comparisons) but had similar major bleeding rates compared with NSTEACS patients ([Table 1](#t1-asm-1-9){ref-type="table"}). Overall 30-day mortality was 7.2% (9.9% in STEMI, 7.1% in NSTEMI, 2.4% in UA, and unknown in 13.7%). Overall 1-year mortality was 9.4% (11.5% in STEMI, 10.1% in NSTEMI, 4.7% in UA, and unknown in 22.9%) ([Table 1](#t1-asm-1-9){ref-type="table"}).

DISCUSSIONS
===========

This report is the first to describe long-term outcomes of ACS patients in the Middle East. It provides a good representation of the clinical management of ACS patients because several hospitals (secondary and tertiary) from all geographic regions of these countries and most health care providers were involved. Our study showed that ACS patients have several unique features and outcomes compared with their counterparts in other populations ([Table 2](#t2-asm-1-9){ref-type="table"}).[@b9-asm-1-9]--[@b23-asm-1-9] Almost half (45.6%) of our patients had STEMI, compared with one-third in other ACS populations reported worldwide. Roger et al reported a decline in the incidence of STEMI over the last 2 decades in a Unites States (US) community-based study.[@b24-asm-1-9] The high prevalence of STEMI in our study is probably the result of the relatively young average age of ACS presentation (56 years), which is almost a decade younger than those of developed countries. [@b9-asm-1-9]--[@b23-asm-1-9] However, the rate of STEMI is very similar to that of ACS patients from the Far East countries, such as Malaysia,[@b25-asm-1-9] but less than the 60.6% rate reported in India.[@b22-asm-1-9] This outcome is likely the result of several factors in addition to the overall younger age of the population in developing countries,[@b26-asm-1-9] including the extremely high prevalence of uncontrolled CAD risk factors in the general population;[@b27-asm-1-9],[@b28-asm-1-9] further, there is the high prevalence of DM, involving 39.5% of our patients. Plausible explanations for this high rate of DM include lack of regular exercise and adopting a "western" diet.[@b29-asm-1-9] These changes in the Arabian culture are probably the result of oil wealth--induced "obesogenic urbanization" that has occurred at a particularly rapid pace over only a few generations.[@b30-asm-1-9] In addition, the high ratio of "expatriates to citizens" living in some Arabian Gulf countries, such as UAE and Qatar, also has contributed to the relatively younger age of ACS presentation. The expatriates are usually much younger, and mostly manual workers with high rates of smoking (53% current smokers in our registry) and a stressful lifestyle compared to Arabian Gulf citizens.

Our STEMI patients took an average of 178 minutes before presenting to the emergency department compared with 140 to 170 minutes in developed countries. [@b12-asm-1-9],[@b17-asm-1-9] The infrequent patient use and/or underdevelopment of ambulance services are among the major reasons for delayed presentations. Other factors include underestimation of the importance of symptoms, absence of a universal health care system provider, traffic congestion in major cities, and long travel distances needed for patients before arrival at a major cardiac center in some Arabian Gulf countries. Moreover, just over one-third of our STEMI patients received TT within the standard 30 minutes because the majority were awaiting approval of administration of TT by the cardiology service, mostly required to receive it in the coronary/intensive care units; further, only half received faster preparations of TT, such as reteplase and tenecteplase. It is important to note that although three quarters of the hospitals are "tertiary-care" centers, and many of the emergency department consultants may not be certified emergency physicians and may prefer to have the cardiology service make the decision for revascularization therapy; this preference can result in further delay in initiating treatment (personal communication with principal investigators).

Primary PCI was done in only 22.3% of STEMI patients, a rate much lower than in developed countries, and only half of them had a DBT within the standard 90 minutes. In addition, 18.8% of STEMI patients did not receive either TT or primary PCI, and did not have an absolute contraindication to either treatment; i.e: reperfusion shortfall; nevertheless, this value is still lower than the 33% reported in the GRACE registry.[@b13-asm-1-9],[@b18-asm-1-9] The reperfusion shortfall was attributable to the fact that the treating physicians either missed the diagnosis or had the "false perception" that the patient would not benefit and might be even harmed by revascularization therapy. This finding highlights the urgent need for initiating educational programs in our region on the establishment of competent triaging systems in the emergency department, and also to improve awareness about the absolute versus relative contraindications for revascularization therapies according to the latest American College of Cardiology/American Heart Association/European Society of Cardiology guidelines. In addition, unavailability of TT and/or coronary catheterization facilities in many hospitals because of the poor economy in some of the Arabian Gulf countries should also be considered.

Similar to recent trends reported by other ACS registries,[@b12-asm-1-9],[@b13-asm-1-9],[@b17-asm-1-9],[@b18-asm-1-9] our study showed a high use of guidelines-recommended oral medications. However, rates of fondaparinux, bivalirudin, GP IIb/IIIa--I, coronary angiography, elective PCI, and CABG were much lower than those reported in developed and some Middle East countries, but similar to those in Asian countries.[@b11-asm-1-9],[@b18-asm-1-9],[@b31-asm-1-9],[@b32-asm-1-9] Less than half of the hospitals involved in our registry had an on-site cardiac catheterization laboratory. These findings reflect the need for establishing more tertiary-care hospitals with high-caliber technical and human resources that could provide more revascularization procedures in a timely fashion for ACS patients. We have reported previously that the use of coronary catheterization was related more to the country's practice pattern and hospital characteristics than to the patient baseline risk.[@b6-asm-1-9],[@b33-asm-1-9] In addition, the elective PCI rate was surprisingly lower in STEMI than in NSTEACS patients despite the presence of more single- and double-vessel CAD in the former. The low rate of timely reperfusion in STEMI patients might have resulted in more myocardial injury, and thus less perceived benefit by the treating physicians about recanalizing the culprit coronary artery by PCI.

The overall in-hospital mortality of 4.6% is similar to contemporary data from developed countries, but lower than those reported in poor communities in India ([Table 2](#t2-asm-1-9){ref-type="table"}). Overall high uses of guidelines-based therapies, in addition to the relatively younger age of ACS presentation, were probably the main reasons for the reasonably low in-hospital mortality in our study. However, we have shown previously a significant disparity in STEMI in-hospital mortality in some Arabian Gulf countries resulting from variability in a number of factors, such as timely presentation, reperfusion therapy, and use of evidence-based medications. [@b34-asm-1-9],[@b35-asm-1-9] STEMI patients had higher in-hospital complications, but similar major bleeding compared to those with NSTEACS. This finding is similar to those of other ACS registries and is most likely related to the long time between symptom onset to hospital arrival and the below-standard door-to-needle times.

The overall mortality rate doubled at 1 year of follow-up (9.4%), however, and was even higher than the mortality rate reported in the Euro Heart Survey ([Table 2](#t2-asm-1-9){ref-type="table"}). This result is alarming because our ACS patients were much younger than those in the developed countries, and yet had higher long-term mortality. This difference might be related to the low rate of coronary revascularization in addition to possible noncompliance with medical therapy and/or healthy lifestyle behaviors after hospital discharge. It is unknown as well whether the use of generic drugs by many hospitals contributed to future cardiovascular events. Furthermore, although STEMI patients had the highest 1-year mortality (11.5%), NSTEMI patients had a severalfold increase in mortality that was proportionally higher than the mortality increase in STEMI patients. This finding is in concordance with the published studies showing a comparable and even a higher long-term mortality for NSTEMI patients, likely because of older age and more cardiovascular and/or noncardiovascular comorbidities.[@b24-asm-1-9]

Our study has several limitations. First, as with most other registries, hospital enrollment was voluntary; thus, the study results may not be representative of clinical practice in all hospitals in the region. In addition, hospitals that participated in the registry might be more enthusiastic about adherence to guidelines and quality improvement initiatives. However, the wide geographic distribution of several hospitals from different health care sectors in our study provides a reasonable overall representation of ACS care. Second, there is an inherent selection bias because of the observational nature of the study design and the possibility of missing unmeasured important covariables. Third, mortality rates might have been underestimated because of missing major adverse events, particularly ACS-related mortality that happened prior to admission to the cardiology service or unknown long-term mortality. We tried to mitigate this issue by requiring all hospitals to enroll consecutive patients and to keep a log book of ACS hospital admissions. Fourth, we did not measure potential factors that might explain the increase in the long-term mortality rates, such as nonadherence to evidence-based therapies. Finally, although we compared our data with other international ACS registries, caution has to be taken about making absolute inferences, mainly because of the patient age and timing differences between these studies and ours.

In conclusion, our study showed that our ACS patients present at a relatively young age and have high rates of DM. STEMI patients delayed a long time before presenting to the hospital, and only a few received either TT or primary PCI within the recommended time-line. In-hospital guidelines-based medication rates were high, but coronary revascularization rates were low. Long-term mortality rates increased severalfold compared with the in-hospital mortality rate, with the highest mortality in STEMI rather than NSTEACS patients, despite the former being younger and having fewer cardiovascular comorbidities. Further studies are needed to explore the underlying reasons for these findings.
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![Medications in the first 24 hours of hospital admission. P\<0.001 for clopidogrel and beta-blockers, *P*\<.002 for statins.](asm-1-9f1){#f1-asm-1-9}

![Medications at hospital discharge. *P*\<.001 for aspirin, clopidogrel, beta-blockers, and ACE-I/ARB, and *P*\<.013 for statins.](asm-1-9f2){#f2-asm-1-9}

![Anticoagulation and GP IIb/IIIa inhibitors. *P*\<.001 for all comparisons. Un. Heparin: unfractionated heparin; LMWH: low molecular weight heparin; GP IIb/IIIa-Inh: glycoprotein IIb/IIIa inhibitors.](asm-1-9f3){#f3-asm-1-9}

###### 

Patient baseline characteristics, procedures, and outcomes in the study.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                  n (%)         STEMI/New LBBB\   NSTEACS\          *P* value
                                                                                                          n (%)             n (%)             
  ----------------------------------------------------------------------------------------- ------------- ----------------- ----------------- -----------
  **Demographics**                                                                                                                            

   Age, mean (SD), years                                                                    56 (17)       54 (16)           58 (17)           \<.001

   Male, n (%)                                                                              6253 (78.8)   3119 (86.1)       3134 (72.6)       \<.001

   Arabian Gulf citizen, n (%)                                                              5674 (71.2)   2366 (65.3)       3308 (76.6)       \<.001

   Body mass index, mean (SD), kg/m^2^[a](#tfn2-asm-1-9){ref-type="table-fn"}               26.2 (5.8)    25.8 (5.5)        26.7 (6.2)        \<.001

   Central obesity, n (%)[b](#tfn3-asm-1-9){ref-type="table-fn"}                            2196 (50.1)   1057 (45.5)       1139 (55.4)       \<.001

   Ambulance use, n (%)[c](#tfn4-asm-1-9){ref-type="table-fn"}                              1325 (19.1)   621 (19.8)        704 (18.5)        .195

  **Initial presentation**                                                                                                                    

   Typical ischemic chest pain, n (%)                                                       6675 (84.1)   3244 (89.6)       3431 (79.5)       \<.001

   Cardiac arrest                                                                           47 (0.59)     28 (0.77)         19 (0.44)         \<.001

   SBP, mean (SD), mm Hg                                                                    132 (35)      130 (40)          138 (36)          \<.001

   DBP, mean (SD), mm Hg                                                                    80 (20)       80 (20)           80 (20)           .164

   HR, mean (SD), bpm                                                                       82 (25)       84 (26)           81 (24)           .339

   Atrial fibrillation, n (%)                                                               166 (2.1)     43 (1.2)          123 (2.8)         \<.001

   Killip class \>1, n (%)                                                                  1822 (23)     765 (21.1)        1057 (24.5)       \<.001

  **History**                                                                                                                                 

   CAD, n (%)                                                                               4548 (57.3)   1110 (30.6)       3438 (79.6)       \<.001

   PCI, n (%)                                                                               727 (9.2)     128 (3.5)         599 (13.9)        \<.001

   CABG, n (%)                                                                              336 (4.2)     36 (1)            300 (6.9)         \<.001

   CHF, n (%)                                                                               523 (6.6)     71 (2)            452 (10.5)        \<.001

   CVA/TIA, n (%)                                                                           341 (4.3)     118 (3.3)         223 (5.2)         \<.001

   PAD, n (%)                                                                               145 (1.8)     39 (1.1)          106 (2.5)         \<.001

   CRF, n (%)                                                                               319 (4)       43 (1.2)          276 (6.4)         \<.001

   Diabetes mellitus, n (%)                                                                 3137 (39.5)   1167 (32.2)       1970 (45.6)       \<.001

   Hypertension, n (%)                                                                      3748 (47.2)   1246 (34.4)       2502 (58.0)       \<.001

   Current smoking, n (%)                                                                   2834 (35.7)   1726 (47.6)       1108 (25.7)       \<.001

   Ex-smoking, d n (%)                                                                      1363 (17.2)   610 (16.8)        753 (17.4)        \<.001

   Khat chewing, n (%)                                                                      1408 (18.4)   983 (27.9)        425 (10.3)        \<.001

   Hyperlipidemia, n (%)                                                                    2598 (32.7)   750 (20.7)        1848 (42.8)       \<.001

  **Laboratory findings**                                                                                                                     

   Positive serum troponin, n (%)[e](#tfn6-asm-1-9){ref-type="table-fn"}                    5426 (68.4)   3124 (86.5)       2302 (53.3)       \<.001

   Peak creatine kinase MB, ng/mL[e](#tfn6-asm-1-9){ref-type="table-fn"}                    49 (103)      94 (152)          18 (35)           \<.001

   Total cholesterol, mmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}                         4.8 (1.9)     5 (1.8)           4.6 (1.9)         \<.001

   Triglyceride, mmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}                              1.5 (1.1)     1.6 (1.1)         1.5 (1.1)         \<.001

   High-density lipoprotein cholesterol, mmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}      1 (0.4)       1 (0.4)           1 (0.4)           .042

   Low-density lipoprotein cholesterol, mmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}       3.1 (1.6)     3.3 (1.5)         2.9 (1.5)         \<.001

   Fasting serum glucose, mmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}                     6.3 (3.3)     6.2 (3.3)         6.3 (3.3)         .864

   HbA1c, %[e](#tfn6-asm-1-9){ref-type="table-fn"}                                          7 (3.2)       7 (3.6)           7 (2.9)           .543

   Serum first creatinine, μmol/L[f](#tfn7-asm-1-9){ref-type="table-fn"}                    88 (33.4)     88 (30.8)         86.3 (34.6)       \<.001

   Serum pre-hospital discharge creatinine, μmol/L[e](#tfn6-asm-1-9){ref-type="table-fn"}   88 (32)       88 (29)           88 (38)           .718

  **GRACE score**                                                                                                                             

   Low, n (%)                                                                               3068 (39.2)   1481 (41.8)       1587 (37.1)       \<.001

   Intermediate, n (%)                                                                      3055 (39.0)   1289 (36.4)       1766 (41.3)       \<.001

   High (%)                                                                                 1702 (21.8)   774 (21.8)        928 (21.7)        .884

  **Procedures (at index hospitalization)**                                                                                                   

   Echocardiography, n (%)                                                                  6073 (76.5)   2881 (79.5)       3192 (73.9)       \<.001

   Mild LV dysfunction, n (%)                                                               2713 (44.7)   1508 (52.4)       1205 (37.8)       \<.001

   Moderate LV dysfunction, n (%)                                                           1198 (19.7)   688 (23.9)        510 (16)          \<.001

   Severe LV dysfunction, n (%)                                                             562 (9.3)     240 (8.3)         322 (10.1)        \<.001

   Coronary angiography, n (%)                                                              2579 (32.5)   979 (27)          1600 (37.1)       \<.001

   Left main disease, n (%)                                                                 146 (5.6)     37 (3.8)          109 (6.8)         .001

   1-vessel disease, n (%)                                                                  762 (29.5)    365 (37.3)        397 (24.7)        \<.001

   2-vessel disease, n (%)                                                                  626 (24.2)    275 (28.1)        351 (21.9)        \<.001

   3-vessel disease, n (%)                                                                  771 (29.8)    228 (23.3)        543 (33.9)        \<.001

   PCI, n (%)[f](#tfn7-asm-1-9){ref-type="table-fn"}                                        1148 (21)     456 (17.3)        692 (24.4)        \<.001

   CABG, n (%)                                                                              233 (2.9)     65 (1.8)          168 (3.9)         \<.001

  **In-hospital outcomes**                                                                                                                    

   Recurrent ischemia                                                                       1233 (15.5)   665 (18.4)        568 (13.2)        \<.001

   Recurrent MI                                                                             172 (2.2)     127 (3.5)         45 (1)            \<.001

   CHF                                                                                      1041 (13.1)   516 (14.2)        525 (12.2)        .006

   Cardiogenic shock                                                                        458 (5.8)     324 (8.9)         134 (3.1)         \<.001

   VT and/or VF                                                                             225 (2.8)     180 (5)           45 (1)            \<.001

   Nonsurgical ventilation                                                                  370 (4.7)     222 (6.1)         148 (3.4)         \<.001

   Stroke                                                                                   56 (0.7)      40 (1.1)          16 (0.4)          \<.001

   Major bleeding                                                                           47 (0.6)      25 (0.7)          22 (0.5)          .296

   Death                                                                                    362 (4.6)     253 (7)           109 (2.5)         \<.001

   Median length of hospital stay, median (IQR), days                                       5.0 (4.0)     5.0 (4.0)         4.0 (3.0)         \<.001

   30-day mortality                                                                         572 (7.21)    356 (9.85)        216 (5)           \<.001

   1-year mortality                                                                         749 (9.43)    417 (11.51)       332 (7.69)        \<.001

  **Total**                                                                                 **7930**      **3613 (45.6)**   **4317 (54.4)**   
  -------------------------------------------------------------------------------------------------------------------------------------------------------

SD: Standard deviation; STEMI: ST-segment elevation myocardial infarction; LBBB: left bundle branch block; NSTEACS: non--ST-segment elevation myocardial infarction; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; bpm: beats per minute; CAD: coronary artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft surgery; CHF: congestive heart failure; CVA/TIA: cerebrovascular accident/transient ischemic attack; PAD: peripheral arterial disease; CRF: chronic renal failure; MI: myocardial infarction; VT: ventricular tachycardia; and VF: ventricular fibrillation; LV: left ventricular.

Unknown serum troponin in 796 (10%) patients.

Data were available for 4385 patients.

Data were available for 6940 patients.

Stopped smoking more than 1 year before index hospitalization.

Median (IQR).

Data were available for PCI in 5462 patients.

###### 

Comparison of acute coronary syndromes in developed and developing countries in the study.

                                                                     NRMI[a](#tfn9-asm-1-9){ref-type="table-fn"},[b](#tfn10-asm-1-9){ref-type="table-fn"} (9--12)   GRACE[c](#tfn11-asm-1-9){ref-type="table-fn"} (13--17)                                  GRACE[d](#tfn12-asm-1-9){ref-type="table-fn"} (18)   EHS 1 and 2[e](#tfn13-asm-1-9){ref-type="table-fn"} (19--21)   CREATE[f](#tfn14-asm-1-9){ref-type="table-fn"} (22)   Gulf RACE[g](#tfn15-asm-1-9){ref-type="table-fn"} (6)   Gulf RACE-2[h](#tfn16-asm-1-9){ref-type="table-fn"} (6)   SPACE[i](#tfn17-asm-1-9){ref-type="table-fn"}
  ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------- -----------------------------------------------
  Patients, n                                                        2 515 106                                                                                      102 341                                                                                 31 982                                               16 183                                                         20 937                                                8176                                                    7930                                                      5055
  Mean age (years)                                                   65--70                                                                                         63--69                                                                                  65                                                   63                                                             57                                                    56                                                      56                                                        58
  History of DM, %                                                   17--35                                                                                         20--30                                                                                  26                                                   21--27                                                         30                                                    40                                                      40                                                        58
  STEMI, %                                                           47                                                                                             30--40                                                                                  30                                                   42--47                                                         61                                                    39                                                      46                                                        41
  NSTEACS, %                                                         53                                                                                             60--70                                                                                  70                                                   48--51                                                         39                                                    61                                                      54                                                        59
  Symptom onset to hospital arrival, median (min)                    132--96[j](#tfn18-asm-1-9){ref-type="table-fn"}                                                140--120[j](#tfn18-asm-1-9){ref-type="table-fn"}                                        133                                                  170--145[j](#tfn18-asm-1-9){ref-type="table-fn"}               300                                                   NA                                                      178                                                       150
  Door-to-needle time, median (min)                                  59--29[j](#tfn18-asm-1-9){ref-type="table-fn"}                                                 40--30[j](#tfn18-asm-1-9){ref-type="table-fn"}                                          32                                                   40--37[j](#tfn18-asm-1-9){ref-type="table-fn"}                 50                                                    45                                                      39                                                        52
  Thrombolytic therapy, %                                            52--28[j](#tfn18-asm-1-9){ref-type="table-fn"}                                                 41--16[j](#tfn18-asm-1-9){ref-type="table-fn"}                                          33                                                   37--41[j](#tfn18-asm-1-9){ref-type="table-fn"}                 59                                                    82                                                      66                                                        69
  Primary PCI, %                                                     2.6--43[j](#tfn18-asm-1-9){ref-type="table-fn"}                                                15--44[j](#tfn18-asm-1-9){ref-type="table-fn"}                                          16                                                   40--58[j](#tfn18-asm-1-9){ref-type="table-fn"}                 8                                                     8                                                       22.3                                                      17.5
  In-hospital mortality,[l](#tfn20-asm-1-9){ref-type="table-fn"} %   8/5.2                                                                                          5.4/2                                                                                   6.2/4.6                                              5.3/2.5                                                        5.6[m](#tfn21-asm-1-9){ref-type="table-fn"}           6.2/1.9                                                 7/2.5                                                     4.5/2
  30-day mortality,[l](#tfn20-asm-1-9){ref-type="table-fn"} %        NA                                                                                             8/3                                                                                     NA                                                   6.4/3.4                                                        8.6/3.8                                               NA                                                      9.9/5                                                     NA
  1-year mortality,[l](#tfn20-asm-1-9){ref-type="table-fn"} %        NA                                                                                             14.8[k](#tfn19-asm-1-9){ref-type="table-fn"},[m](#tfn21-asm-1-9){ref-type="table-fn"}   NA                                                   7/5                                                            NA                                                    NA                                                      11.5/7.7                                                  NA

DM: Diabetes mellitus; STEMI: ST-segment elevation myocardial infarction; NSTEACS: non--ST-segment elevation myocardial infarction; NA: not available; PCI: percutaneous coronary intervention; GRACE: Global Registry of Acute Coronary Events; Gulf RACE: Gulf Registry of Acute Coronary Events; SPACE: Saudi project for assessment of coronary events;

Did not include patients with unstable angina.

National registry of myocardial infarction in the USA.

Global Registry of Acute Coronary Syndromes.

Expanded Global Registry of Acute Coronary Syndromes.

European Heart Surveys 1 and 2.

Treatment and outcomes of acute coronary syndromes in India.

Gulf Registry of Acute Coronary Events.

Gulf Registry of Acute Coronary Events-Phase 2.

Saudi Project for Assessment of Coronary Events (in press).

Data reflect temporal trends chronologically over the years.

Total mortality was derived from 1143 acute coronary syndrome patients enrolled in New Zealand.

STEMI/NSTEACS.

Total in-hospital mortality.
